Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments
暂无分享,去创建一个
[1] P. Mandl,et al. Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis , 2021, Annals of the Rheumatic Diseases.
[2] Andrew T. Kroger,et al. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3 , 2021, Arthritis & rheumatology.
[3] M. Boers,et al. Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies , 2021, The Lancet Rheumatology.
[4] K. Stiasny,et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity , 2021, Annals of the Rheumatic Diseases.
[5] G. Shefer,et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study , 2021, Annals of the Rheumatic Diseases.
[6] Y. Braun-Moscovici,et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2 , 2021, Annals of the Rheumatic Diseases.
[7] L. Du,et al. SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies , 2021, Signal Transduction and Targeted Therapy.
[8] E. Walsh,et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.
[9] Nguyen H. Tran,et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial , 2020, The Lancet.
[10] J. Mascola,et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.
[11] M. Dougados,et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases , 2019, Annals of the rheumatic diseases.
[12] M. Genovese,et al. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept , 2016, BMC Musculoskeletal Disorders.
[13] E. Bonfá,et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis , 2013, Arthritis care & research.
[14] M. Bokarewa,et al. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment , 2010, Arthritis research & therapy.
[15] C. Kallenberg,et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. , 2010, Arthritis and rheumatism.